These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 6863976)
1. Inhibition of a Langerhans cell-mediated immune response by treatment modalities useful in psoriasis. Morhenn VB; Orenberg EK; Kaplan J; Pfendt E; Terrell C; Engleman EG J Invest Dermatol; 1983 Jul; 81(1):23-7. PubMed ID: 6863976 [TBL] [Abstract][Full Text] [Related]
2. An investigation of the ability of antipsoriatic drugs to inhibit calmodulin activity: a possible mode of action of dithranol (anthralin). Tucker WF; MacNeil S; Dawson RA; Tomlinson S; Bleehen SS J Invest Dermatol; 1986 Aug; 87(2):232-5. PubMed ID: 3016102 [TBL] [Abstract][Full Text] [Related]
3. Immunologic mechanisms in psoriasis. Gottlieb AB J Am Acad Dermatol; 1988 Jun; 18(6):1376-80. PubMed ID: 3290292 [TBL] [Abstract][Full Text] [Related]
4. Comparison of antiproliferative effects of experimental and established antipsoriatic drugs on human keratinocytes, using a simple 96-well-plate assay. Pol A; Bergers M; Schalkwijk J In Vitro Cell Dev Biol Anim; 2003; 39(1-2):36-42. PubMed ID: 12892525 [TBL] [Abstract][Full Text] [Related]
5. The autologous mixed epidermal cell-T lymphocyte reaction is elevated in psoriasis: a crucial role for epidermal HLA-DR+/CD1a- antigen-presenting cells. Prens EP; Benne K; van Joost T; Benner R J Invest Dermatol; 1991 Jun; 96(6):880-7. PubMed ID: 1710638 [TBL] [Abstract][Full Text] [Related]
6. Effects of topical corticosteroid therapy on Langerhans cell antigen presenting function in human skin. Ashworth J; Booker J; Breathnach SM Br J Dermatol; 1988 Apr; 118(4):457-69. PubMed ID: 3288268 [TBL] [Abstract][Full Text] [Related]
7. Langerhans' cells in patients with psoriasis: effect of treatment with PUVA, PUVA bath, etretinate and anthralin. Czernielewski J; Juhlin L; Shroot S; Brun P Acta Derm Venereol; 1985; 65(2):97-101. PubMed ID: 2408430 [TBL] [Abstract][Full Text] [Related]
8. T-lymphocyte-activating properties of epidermal antigen-presenting cells from normal and psoriatic skin: evidence that psoriatic epidermal antigen-presenting cells resemble cultured normal Langerhans cells. Demidem A; Taylor JR; Grammer SF; Streilein JW J Invest Dermatol; 1991 Sep; 97(3):454-60. PubMed ID: 1875046 [TBL] [Abstract][Full Text] [Related]
9. The antipsoriatic drug, anthralin, inhibits protein kinase C--implications for its mechanism of action. Hegemann L; Fruchtmann R; van Rooijen LA; Müller-Peddinghaus R; Mahrle G Arch Dermatol Res; 1992; 284(3):179-83. PubMed ID: 1503504 [TBL] [Abstract][Full Text] [Related]
10. Density of epidermal Langerhans cells in psoriasis patients treated with an aromatic retinoid (RO 10-9359). An immunoperoxidase study using anti-T6 and anti-Ia monoclonal antibodies. Guzman de Fleury M; Tapia FJ; Soto J; Ghersi N; Convit J Histol Histopathol; 1986 Jul; 1(3):227-34. PubMed ID: 2856536 [TBL] [Abstract][Full Text] [Related]
12. A simple technique for high-throughput screening of drugs that modulate normal and psoriasis-like differentiation in cultured human keratinocytes. Pol A; Bergers M; van Ruissen F; Pfundt R; Schalkwijk J Skin Pharmacol Appl Skin Physiol; 2002; 15(4):252-61. PubMed ID: 12218287 [TBL] [Abstract][Full Text] [Related]
13. The interleukin-8 receptor: a potential target for antipsoriatic therapy? Kemény L; Kenderessy AS; Olasz E; Michel G; Ruzicka T; Farkas B; Dobozy A Eur J Pharmacol; 1994 Jun; 258(3):269-72. PubMed ID: 8088360 [TBL] [Abstract][Full Text] [Related]
14. Anthralin derivatives--inhibition of 5-lipoxygenase--antipsoriatic efficacy. Tanzer H; Braun C; Seidel M; Wiegrebe W Arch Pharm (Weinheim); 1991 Nov; 324(11):841-6. PubMed ID: 1804060 [TBL] [Abstract][Full Text] [Related]
15. Magnesium ions inhibit the antigen-presenting function of human epidermal Langerhans cells in vivo and in vitro. Involvement of ATPase, HLA-DR, B7 molecules, and cytokines. Schempp CM; Dittmar HC; Hummler D; Simon-Haarhaus B; Schulte-Mönting J; Schöpf E; Simon JC J Invest Dermatol; 2000 Oct; 115(4):680-6. PubMed ID: 10998143 [TBL] [Abstract][Full Text] [Related]
16. Antipsoriatic and proinflammatory action of anthralin. Implications for the role of oxygen radicals. Müller K Biochem Pharmacol; 1997 May; 53(9):1215-21. PubMed ID: 9214681 [TBL] [Abstract][Full Text] [Related]
17. Mixed epidermal cell lymphocyte reaction: HLA-DR+ cells exhibit a greater immunostimulatory activity than CD1a+ cells. Dobmeyer TS; Dobmeyer JM; Klein SA; Schopf RE; Helm EB; Rossol R Adv Exp Med Biol; 1995; 378():393-6. PubMed ID: 8526102 [No Abstract] [Full Text] [Related]
18. Langerhans cells in skin from patients with psoriasis: quantitative and qualitative study of T6 and HLA-DR antigen-expressing cells and changes with aromatic retinoid administration. Haftek M; Faure M; Schmitt D; Thivolet J J Invest Dermatol; 1983 Jul; 81(1):10-4. PubMed ID: 6345681 [TBL] [Abstract][Full Text] [Related]
19. Mechanisms of cyclosporine A inhibition of antigen-presenting activity in uninvolved and lesional psoriatic epidermis. Cooper KD; Baadsgaard O; Ellis CN; Duell E; Voorhees JJ J Invest Dermatol; 1990 May; 94(5):649-56. PubMed ID: 2324521 [TBL] [Abstract][Full Text] [Related]
20. Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. Gottlieb AB; Lifshitz B; Fu SM; Staiano-Coico L; Wang CY; Carter DM J Exp Med; 1986 Oct; 164(4):1013-28. PubMed ID: 2428913 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]